Onconova Therapeutics Inc. To Participate In Panel Discussions At Two Investor Conferences In December

NEWTOWN, Pa., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will participate in an oncology innovator panel during the Piper Jaffray 27th Annual Healthcare Conference and a personalized medicine panel during the 2015 Life Sciences Summit. Details for the panels are below:

Life Sciences Summit 2015
Title of Panel: Immuno-oncology & Precision Medicine: The Double Whammy in Cancer Therapies
Focus of Company Presentation: Epigenetic analysis for identifying lower-risk myelodysplastic syndromes (MDS) patients for clinical trials
Date: 12/1/2015
Time: 1:15 PM ET
Location: 10 on the Park, Time Warner Center, New York, NY
Piper Jaffray 27th Annual Healthcare Conference
Title of Panel: Underdiscovered OncoInnovators
Focus of Company Presentation: Identifying molecularly targeted patient subgroups suitable for additional clinical trials in MDS
Date: 12/1/2015
Time: 3:00 PM ET
Location: Lotte New York Palace, New York, NY

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com.

Back to news